Document is current
Any future updates will be listed below
-
Authors
Wu, Fan https://orcid.org/0000-0002-5953-4168
Yang, Linlin
Hang, Kaini
Laursen, Mette https://orcid.org/0000-0002-6265-2069
Wu, Lijie
Han, Gye Won
Ren, Qiansheng
Roed, Nikolaj Kulahin
Lin, Guangyao
Hanson, Michael A.
Jiang, Hualiang
Wang, Ming-Wei https://orcid.org/0000-0001-6550-9017
Reedtz-Runge, Steffen https://orcid.org/0000-0002-9216-3311
Song, Gaojie https://orcid.org/0000-0002-7787-6452
Stevens, Raymond C.
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (81872915, 31770898)
- License Information
-
More Information
Article History
Received: 13 November 2019
Accepted: 7 February 2020
First Online: 9 March 2020
Competing interests
: S.R.-R. is an employee of Novo Nordisk, a pharmaceutical company focused on GLP-1R for type 2 diabetes. R.C.S. is a founder and board member of Bird Rock Bio, a company focused on GPCR therapeutic antibodies. R.C.S. is a founder, board member, and employee of ShouTi, a company focused on GPCR small molecules. M.A.H. is a founder and employee of ShouTi. The remaining authors declare no competing interests.
